<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1987">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081546</url>
  </required_header>
  <id_info>
    <org_study_id>16-1954</org_study_id>
    <nct_id>NCT03081546</nct_id>
  </id_info>
  <brief_title>Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease</brief_title>
  <official_title>Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to assess the effectiveness of performance-based functional assessments&#xD;
      (PBFAs) and cognitive assessments in diagnosing Alzheimer's disease in Hispanic/Latino&#xD;
      populations. The information from this study will be analyzed with data from the Rocky&#xD;
      Mountain Alzheimer's Disease Center Bio-AD study (NCT02612376).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2017</start_date>
  <completion_date type="Actual">September 1, 2018</completion_date>
  <primary_completion_date type="Actual">September 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>University of California San Diego (UCSD) Performance-Based Skills Assessment (UPSA)</measure>
    <time_frame>30 minutes</time_frame>
    <description>Measure independent functioning in everyday life for controls and individuals with MCI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication Management Ability Assessment</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measure independent management of medications in controls and individuals with MCI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lawton iADL (instrumental activities of daily living) scale</measure>
    <time_frame>5 minutes</time_frame>
    <description>Measure ability to perform instrumental activities of daily living in controls and individuals with MCI</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">41</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment (MCI)</arm_group_label>
    <description>Persons with age-related Mild Cognitive Impairment (MCI) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria.&#xD;
Must be concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Community dwelling controls older than 55 years of age that are concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Mild Cognitive Impairment and healthy aging adults&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persons with age-related MCI or AD according to clinical diagnosis, consistent with&#xD;
             National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria&#xD;
&#xD;
          -  Community-dwelling controls&#xD;
&#xD;
          -  Age &gt; 55 years&#xD;
&#xD;
          -  Have been enrolled and completed at least one visit in the Bio-AD study and consent to&#xD;
             access their data (the Rocky Mountain Alzheimer's Disease Center Bio-AD study&#xD;
             (clinicaltrials.gov identifier: NCT02612376))&#xD;
&#xD;
          -  Have capacity to provide consent; capacity will be assessed at the time of consent&#xD;
&#xD;
          -  Ability to complete baseline assessments&#xD;
&#xD;
          -  Has informant (study partner) available to complete functional interviews/survey&#xD;
             measures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of concomitant medical, neurological, or psychiatric illness or condition&#xD;
             that in the opinion of the investigators would confound interpretation of study&#xD;
             results. These include:&#xD;
&#xD;
          -  Korsakoff encephalopathy;&#xD;
&#xD;
          -  active substance abuse;&#xD;
&#xD;
          -  hepatitis C;&#xD;
&#xD;
          -  opportunistic brain infection;&#xD;
&#xD;
          -  brain tumor;&#xD;
&#xD;
          -  active neoplastic disease (skin tumors other than melanoma are not exclusionary;&#xD;
             participants with stable prostate cancer may be included at the discretion of the&#xD;
             project director);&#xD;
&#xD;
          -  multiple sclerosis;&#xD;
&#xD;
          -  history of clinically significant stroke;&#xD;
&#xD;
          -  current evidence or history in the past 2 years of&#xD;
&#xD;
               -  focal brain lesion,&#xD;
&#xD;
               -  head injury with loss of consciousness in the past year, or&#xD;
&#xD;
               -  DSM-5 criteria for any major psychiatric disorder, including&#xD;
&#xD;
                    1. psychosis,&#xD;
&#xD;
                    2. uncontrolled major depression,&#xD;
&#xD;
                    3. bipolar disorder,&#xD;
&#xD;
                    4. alcohol or substance abuse;&#xD;
&#xD;
                    5. blindness,&#xD;
&#xD;
                    6. deafness or&#xD;
&#xD;
                    7. any other disability which may prevent the participant from participating or&#xD;
                       cooperating in the protocol.&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Any contraindication for MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis Medina, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2017</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

